Elixinol Wellness Ltd Completes US Business Sale to Focus on Australia

Elixinol Wellness has completed its Elixinol Wellness US Business Divestment, selling to Ananda Health for up to A$465,000 while retaining global brand IP — here's what the deal terms and going concern context mean for investors.
By Josua Ferreira -
  • Elixinol Wellness completed the sale of its US business to Ananda Health on 4 September 2026, with total headline consideration of approximately A$465,000 comprising A$250,000 upfront and up to A$215,000 in deferred and contingent payments.
  • The A$250,000 upfront payment was released from escrow and is expected to be received on 7 September 2026, while the remaining proceeds depend on a regulatory contingent payment and a revenue-based earn-out tied to Ananda Health's performance.
  • EXL retains full rights to the Elixinol brand and intellectual property outside the US territory under the terms of the asset purchase agreement.
  • Settlement of the divestment resolves one of three dependencies underpinning the going concern assessment disclosed in EXL's H1 FY26 interim report, with cash flow forecasts and Convertible Note proceeds remaining as live conditions.
  • The completed sale narrows EXL's operational footprint to its Australian portfolio, which spans five brands across retail, ingredient, grocery, wholesale, and e-commerce channels.
Summarise with AI:

US divestment completed as Elixinol sharpens focus on Australian portfolio

Elixinol Wellness Limited (ASX: EXL) has completed the sale of its US business to Ananda Health, Inc., with the transaction settling on Friday 4 September 2026 in accordance with the asset purchase agreement announced on 31 August 2026.

The divestment simplifies the Group’s operations, reduces its exposure to the evolving US regulatory environment and enables the company to focus its resources on its Australian health and wellness portfolio.

The sale carries headline consideration of approximately A$465,000, comprising upfront and deferred consideration, including a regulatory contingent payment and a revenue-based earn-out.

Deal terms and the consideration breakdown

The consideration is structured across upfront and future payments. The upfront consideration of A$250,000 has been released from the escrow account and is expected to be received by EXL on 7 September 2026.

The binding offer from Ananda Health was announced on 31 August 2026, conditional on loan note holder consents and structured so that EXL retains full rights to the Elixinol brand and IP outside the US territory.

Following payment of the upfront amount, the remaining consideration payable comprises deferred and contingent proceeds of up to A$215,000. This includes the regulatory contingent payment and the revenue-based earn-out referenced in the Agreement.

US Divestment Consideration Breakdown

Consideration Component Amount Status
Upfront consideration A$250,000 Released from escrow, expected received 7 September 2026
Deferred and contingent proceeds Up to A$215,000 Payable under the Agreement
Total headline consideration Approximately A$465,000 Upfront plus deferred and contingent

Completion conditions satisfied and transition underway

Each of the conditions to completion was satisfied ahead of settlement. According to the announcement, these were:

  • Completion of due diligence

  • No material adverse change

  • Receipt of the required consents from the loan note holders that held security over the US business

Transitional arrangements have commenced to support an orderly transfer of the business. These cover operational, customer service, marketing and other support, for a period of up to six weeks following completion.

What a divestment means for investors

A divestment is the sale or disposal of a business unit, asset or subsidiary. Companies commonly divest operations that are non-core or that carry regulatory complexity, allowing them to redirect capital and management attention towards areas viewed as central to their strategy.

In EXL’s case, exiting the US removes exposure to what the company describes as an evolving US regulatory environment. It also frees resources for the Australian business, narrowing the Group’s operational footprint to a single market. For investors, a simpler structure can make performance easier to assess, though the announcement does not disclose any financial impact figures beyond the consideration terms.

A going concern disclosure remained in EXL’s H1 FY26 interim report, with the Directors’ assessment resting simultaneously on cash flow forecasts, Convertible Note proceeds, and US divestment completion all holding, making the settlement of this transaction a key dependency for the near-term financial position.

Renewed focus on the Australian wellness portfolio

The completed sale allows EXL to concentrate on its vertically integrated Australian healthy food business, which spans nutrition, wellness and superfood ingredient verticals.

The domestic platform includes:

  • Retail brands: The Healthy Chef, Hemp Foods Australia and Mt Elephant

  • Ingredient brands: Australian Primary Hemp and The Australian Superfood Co

  • Channels: grocery, wholesale and e-commerce

A leaner, single-market focus positions the company around a clearer domestic growth story, with products distributed across its established retail and ingredient brands. The announcement was authorised for release by the Board of Elixinol Wellness Limited.

Don’t Miss the Next Consumer Sector Move on the ASX

Big News Blast delivers FREE breaking ASX news straight to your inbox within minutes of release, complete with in-depth analysis already done for you. Join 20,000+ investors who stay ahead of the market the moment announcements drop. Click the “Free Alerts” button at Big News Blast to start receiving alerts today.


Frequently Asked Questions

What is the Elixinol Wellness US business divestment?

Elixinol Wellness (ASX: EXL) sold its US business to Ananda Health, Inc., with the transaction settling on 4 September 2026 for total headline consideration of approximately A$465,000, comprising A$250,000 upfront and up to A$215,000 in deferred and contingent payments.

Does Elixinol keep its brand after selling the US business?

Yes — the asset purchase agreement was structured so that EXL retains full rights to the Elixinol brand and intellectual property outside the US territory, meaning the brand remains available for use in Australia and other international markets.

What does the US divestment mean for Elixinol's going concern status?

The H1 FY26 interim report included a going concern disclosure where the Directors' assessment depended on cash flow forecasts, Convertible Note proceeds, and US divestment completion all holding — the settlement of the divestment resolves one of those three dependencies, but the others remain outstanding.

What Australian brands does Elixinol own after the US sale?

Following the divestment, EXL's Australian portfolio includes retail brands The Healthy Chef, Hemp Foods Australia, and Mt Elephant, plus ingredient brands Australian Primary Hemp and The Australian Superfood Co, distributed across grocery, wholesale, and e-commerce channels.

When will Elixinol receive the money from the US business sale?

The upfront consideration of A$250,000 was released from escrow and is expected to be received by EXL on 7 September 2026, with the remaining deferred and contingent proceeds of up to A$215,000 payable under the terms of the agreement at future dates.

Josua Ferreira
By Josua Ferreira
Partnership Director
Josua Ferreira holds a Bachelor of Commerce in Marketing and Advertising and brings a background in publication, business development, and ASX market storytelling. He has worked with listed companies across the resource sector and broader market, combining sharp commercial instincts with a genuine commitment to keeping investors informed.
Learn More
Companies Mentioned in Article

Breaking ASX Alerts Direct to Your Inbox

Join +20,000 subscribers receiving alerts.

Join thousands of investors who rely on StockWire X for timely, accurate market intelligence.

About the Publisher